These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17536251)

  • 1. Challenges in the anticipation of biosimilars: how must a P&T committee gear up?
    Tadlock C
    Manag Care Interface; 2007 Apr; 20(4):12, 14. PubMed ID: 17536251
    [No Abstract]   [Full Text] [Related]  

  • 2. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

  • 3. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

  • 4. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving pharmacy and therapeutics committee operations.
    Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE
    Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The chairman of the drug committees: limit the reporting requirement between pharmacy and the prescribing physician concerning generic drug exchange].
    Back S; Widäng K
    Lakartidningen; 2002 Dec; 99(49):5005. PubMed ID: 12522991
    [No Abstract]   [Full Text] [Related]  

  • 7. Should you go generic?
    Carmichael M
    Newsweek; 2008 Oct; 152(15):78. PubMed ID: 18975394
    [No Abstract]   [Full Text] [Related]  

  • 8. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 9. NerveCenter: FDA requirements for generic drug applications.
    Ann Neurol; 2010 Sep; 68(3):A11. PubMed ID: 20818779
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory aspects of biosimilars in Europe.
    Zuñiga L; Calvo B
    Trends Biotechnol; 2009 Jul; 27(7):385-7. PubMed ID: 19467723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic and alternative brand-name pharmaceutical equivalents: select with caution.
    Hendeles L; Hochhaus G; Kazerounian S
    Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilars legislation awakens data exclusivity debate.
    Hutson S
    Nat Med; 2009 Nov; 15(11):1242. PubMed ID: 19893548
    [No Abstract]   [Full Text] [Related]  

  • 13. Increasing stakes and complex dynamics in the formulary process.
    Tadlock C
    Manag Care Interface; 2007 Mar; 20(3):12, 14. PubMed ID: 17458473
    [No Abstract]   [Full Text] [Related]  

  • 14. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 15. Greater access to generic drugs. New FDA initiatives to improve drug reviews and reduce legal loopholes.
    Meadows M
    FDA Consum; 2003; 37(5):12-7. PubMed ID: 14666900
    [No Abstract]   [Full Text] [Related]  

  • 16. In U.S., biosimilars still await FDA decision.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
    [No Abstract]   [Full Text] [Related]  

  • 17. WHO pulls Indian generics off AIDS drugs list.
    Nat Med; 2004 Sep; 10(9):885. PubMed ID: 15340402
    [No Abstract]   [Full Text] [Related]  

  • 18. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 19. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
    Cross M
    Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
    [No Abstract]   [Full Text] [Related]  

  • 20. Generic drug substitution.
    Rogowski A; Lemay V
    Med Health R I; 2001 Jul; 84(7):241-4. PubMed ID: 11482281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.